Cargando…
Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis
BACKGROUND: Treatment of latent tuberculosis infection (LTBI) in high-risk groups is an effective strategy for TB control and elimination in low incidence settings. A nine-month course of daily isoniazid (INH) has been the longest prescribed therapy; however, completion rates are suboptimal. We need...
Autores principales: | Séraphin, Marie Nancy, Hsu, HsiaoChu, Chapman, Helena J., de Andrade Bezerra, Joanne L., Johnston, Lori, Yang, Yang, Lauzardo, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724263/ https://www.ncbi.nlm.nih.gov/pubmed/31481046 http://dx.doi.org/10.1186/s12889-019-7524-4 |
Ejemplares similares
-
Short‐course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
por: Liou, Bo‐Huang, et al.
Publicado: (2021) -
Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital
por: Chung, Sung Jun, et al.
Publicado: (2020) -
3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review
por: Assefa, Yibeltal, et al.
Publicado: (2018) -
The impact of COVID-19 pandemic on hospital admissions for nine diseases in Iran: insight from an interrupted time series analysis
por: Ahmadi, Sina, et al.
Publicado: (2022) -
Time Course and Risk Profile of Work-Related Neck Disability: A Longitudinal Latent Class Growth Analysis
por: Xie, Yanfei, et al.
Publicado: (2022)